905 Bupropion for smoking cessation in patients hospitalized with acute myocardial infarction: A randomized, placebo-controlled trial

Mm, Eisenberg; Grandi, Sonia M.; Gervais, André; Joseph, Lawrence; O’Loughlin, John; Paradis, Gilles; Rinfret, Stéphane; Sarrafzadegan, N.; Sharma, Swati; Lauzon, Claude; Yadav, R.; Pilote, Louise

doi:10.1016/j.cjca.2011.07.616

Cited by 23 publications

(38 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…4,5 Little is known about current trends in SC after PCI and about the potential impact of smoke-free policies and SC therapies 6 on SC and subsequent health outcomes after PCI. To help shed light on these issues, we assessed the trends and predictors of SC after PCI in Olmsted County, Minnesota, during the enactment of local and statewide smoke-free public policies (time frame of the PCI was January 1, 1999, to December 31, 2009, with 12 months of follow-up).…”

mentioning

confidence: 99%

Trends and Predictors of Smoking Cessation After Percutaneous Coronary Intervention (from Olmsted County, Minnesota, 1999 to 2010)

Sochor¹,

Lennon²,

Rodriguez-Escudero³

et al. 2015

The American Journal of Cardiology

View full text Add to dashboard Cite

mentioning

confidence: 99%

Trends and Predictors of Smoking Cessation After Percutaneous Coronary Intervention (from Olmsted County, Minnesota, 1999 to 2010)

Sochor¹,

Lennon²,

Rodriguez-Escudero³

et al. 2015

The American Journal of Cardiology

View full text Add to dashboard Cite

“…47 In addition, an observational study conducted by the US Mini-Sentinel system found no evidence of an increased risk. 48 On the basis of the available evidence, the US Food and Drug Administration has concluded that, although an increased risk of major cardiovascular events cannot be ruled out, the health benefits attributable to increased cessation with varenicline suggest that benefits likely outweigh potential harms. 49 Concerns of neuropsychiatric harms of varenicline and bupropion also exist, including changes in mood (including depression and mania), psychosis, hallucinations, paranoia, delusions, homicidal ideation, hostility, agitation, aggression, anxiety, and panic, as well as suicidal ideation, suicide attempt, and completed suicide.…”

mentioning

confidence: 99%

Efficacy and Safety of Smoking Cessation Interventions in Patients With Cardiovascular Disease

Suissa

Larivière

Eisenberg³

et al. 2017

Circ: Cardiovascular Quality and Outcomes

View full text Add to dashboard Cite

1T he efficacy and safety of pharmacological and behavioral smoking cessation interventions have been examined in multiple randomized controlled trials (RCTs), with subsequent meta-analyses showing that such interventions are efficacious at increasing quit rates.1,2 However, participants in these trials were generally healthy, and the generalizability of these data to patients with cardiovascular disease (CVD) is unclear. This unclear generalizability is underscored by 3 trials that found that the smoking cessation drug bupropion did not increase the prevalence of abstinence when used in patients with acute manifestations of CVD. [3][4][5] This may be because of fundamental differences between such patients, who tend to have higher quit rates without therapy because of an increased motivation to quit and the teachable moment that occurs after an adverse event, 6 and the otherwise healthy smokers enrolled in previous RCTs. 6,7 Similarly, the generalizability of RCTs conducted in the general population to patients with stable CVD is also unknown. A thorough assessment of the effect of smoking cessation interventions in CVD patients is needed to develop tailored recommendations to increase abstinence in the CVD population. Consequently, we conducted a systematic review and network meta-analysis of RCTs to evaluate the relative efficacy and safety of pharmacological and behavioral smoking cessation interventions in CVD patients.Background-Although the efficacy and safety of smoking cessation interventions are well established, their efficacy and safety in patients with cardiovascular disease (CVD) remain unclear. The objective of this study was to evaluate the efficacy and safety of pharmacological and behavioral smoking cessation interventions in CVD patients via a metaanalysis of randomized controlled trials. Methods and Results-EMBASE, PsycINFO, MEDLINE, PubMed, and the Cochrane Tobacco Addiction SpecializedRegister were searched for randomized controlled trials evaluating the efficacy of smoking cessation pharmacotherapies and behavioral therapies in CVD patients. Outcomes of interest were smoking abstinence at 6 and 12 months, defined using the most rigorous criteria reported. Data were pooled across studies for direct comparisons using random-effects models. Network meta-analysis using a graph-theoretical approach was used to generate the indirect comparisons. Seven pharmacotherapy randomized controlled trials (n=2809) and 17 behavioral intervention randomized controlled trials (n=4666) met our inclusion criteria. Our network meta-analysis revealed that varenicline (relative risk [ MethodsOur systematic review and network meta-analysis was performed after a prespecified protocol and is reported using the guidelines described in PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) extension for reporting of systematic reviews incorporating network meta-analyses. 8 Data SourcesWe systematically searched Ovid EMBASE, Ovid PsycINFO, Ovid MEDLINE, PubMed, and the Cochrane Tobacco Addiction G...

show abstract

“…[8][9][10] Varenicline, a partial agonist of α4β2 nicotinic acetylcholine receptors, has been widely studied in the general population, with efficacy appearing to meet or exceed that of nicotine replacement therapies and bupropion. [11][12][13] Along with bupropion, varenicline has been shown to increase abstinence in patients with stable cardiovascular disease; however, its efficacy in patients with acute coronary syndrome was previously unknown.…”

mentioning

confidence: 99%

Smoking abstinence 1 year after acute coronary syndrome: follow-up from a randomized controlled trial of varenicline in patients admitted to hospital

Windle

Dehghani

Roy

et al. 2018

CMAJ

View full text Add to dashboard Cite

905 Bupropion for smoking cessation in patients hospitalized with acute myocardial infarction: A randomized, placebo-controlled trial

Cited by 23 publications

References 0 publications

Trends and Predictors of Smoking Cessation After Percutaneous Coronary Intervention (from Olmsted County, Minnesota, 1999 to 2010)

Trends and Predictors of Smoking Cessation After Percutaneous Coronary Intervention (from Olmsted County, Minnesota, 1999 to 2010)

Efficacy and Safety of Smoking Cessation Interventions in Patients With Cardiovascular Disease

Smoking abstinence 1 year after acute coronary syndrome: follow-up from a randomized controlled trial of varenicline in patients admitted to hospital

Contact Info

Product

Resources

About